As clinicians, teachers, and lifelong learners, we are constantly challenged to convert evolving science into everyday care. This volume is our collective attempt to do precisely that: curate state-of-the-art urological knowledge and distil it into clear, practice-ready guidance for residents, fellows, and practising urologists alike.
A recurring theme across these chapters is precision: the insistence that our diagnoses and decisions be anchored to biology, not merely morphology or habit. The opening chapters on bladder cancer exemplify this shift. Immunohistochemistry is positioned not as a “special stain,” but as a clinical instrument—clarifying CIS versus reactive atypia; enabling luminal–basal subtyping with GATA3 and CK5/6; and improving staging with smoothelin, where millimetres determine treatment. Equally, the focused appraisal of HER2 reminds us that a receptor can be a diagnostic signal, a prognostic lens, and a therapeutic doorway. From antibody-drug conjugates to rational combinations with immunotherapy, the arc is unmistakable: biomarkers are now care pathways.
Edited by
Prof Dr Sriram Krishnamoorthy
Department of Urology & Renal Transplantation, Sri Ramachandra Institute of Higher Education & Research, Chennai, India.
ISBN 978-93-47485-68-8 (Print)
ISBN 978-93-47485-08-4 (eBook)
DOI: https://doi.org/10.9734/bpi/mono/978-93-47485-68-8
As clinicians, teachers, and lifelong learners, we are constantly challenged to convert evolving science into everyday care. This volume is our collective attempt to do precisely that: curate state-of-the-art urological knowledge and distil it into clear, practice-ready guidance for residents, fellows, and practising urologists alike.
A recurring theme across these chapters is precision: the insistence that our diagnoses and decisions be anchored to biology, not merely morphology or habit. The opening chapters on bladder cancer exemplify this shift. Immunohistochemistry is positioned not as a “special stain,” but as a clinical instrument—clarifying CIS versus reactive atypia; enabling luminal–basal subtyping with GATA3 and CK5/6; and improving staging with smoothelin, where millimetres determine treatment. Equally, the focused appraisal of HER2 reminds us that a receptor can be a diagnostic signal, a prognostic lens, and a therapeutic doorway. From antibody-drug conjugates to rational combinations with immunotherapy, the arc is unmistakable: biomarkers are now care pathways.
Media Promotion:
Contents
Bridging Molecular Insights and Technological Innovation: The Emerging Frontiers in Urology
Venkateshen Palaniyandi, Sriram Krishnamoorthy
Immunohistochemistry in Bladder Cancer: Diagnostic, Prognostic, and Molecular Subtyping Applications
Vijayanand Mani, Bhavyadeep Korrapati, Vivek Meyyappan, Velmurugan Palaniyandi, Hariharasudhan Sekar, Sriram Krishnamoorthy
HER2 in Bladder Cancer: Molecular Biology, Prognostic Value, and Emerging Therapeutic Strategies
Vijayanand Mani, Bhavyadeep Korrapati, Velmurugan Palaniyandi, Hariharasudhan Sekar, Sriram Krishnamoorthy
Scoring Systems for Inflammatory and Traumatic Urethral Strictures
Bhavyadeep Korrapati, Vijayanand Mani, Vivek Meyyappan, Velmurugan Palaniyandi, Hariharasudhan Sekar, Sriram Krishnamoorthy
Supine Percutaneous Nephrolithotomy (PCNL): Current Status
Bhavyadeep Korrapati, Vijayanand Mani, Velmurugan Palaniyandi, Hariharasudhan Sekar, Sriram Krishnamoorthy
Innovations in Flexible Ureterorenoscopy for Renal Stones
Rajan Ravichandran, Roshan Reddy, Vivek Meyyappan, Velmurugan Palaniyandi, Hariharasudhan Sekar, Sriram Krishnamoorthy
Angiogenesis in Renal Cell Carcinoma: Molecular Biology, Clinical Manifestations, and Case-Based Insights
Rajan Ravichandran, Roshan Reddy, Vivek Meyyappan, Velmurugan Palaniyandi, Hariharasudhan Sekar, Sriram Krishnamoorthy
Renal Papillary Necrosis in Acute Pyelonephritis: Pathogenesis, Diagnosis, and the Role of Relook Flexible Ureterorenoscopy
Suryaram Aravind, Punith Jain, Hariharasudhan Sekar, Velmurugan Palaniyandi, Vivek Meyyappan, Sriram Krishnamoorthy